{
    "clinical_study": {
        "@rank": "136247", 
        "acronym": "BOOSTER", 
        "arm_group": [
            {
                "arm_group_label": "Arm A", 
                "arm_group_type": "Active Comparator", 
                "description": "weekly paclitaxel + bevacizumab"
            }, 
            {
                "arm_group_label": "Arm B", 
                "arm_group_type": "Experimental", 
                "description": "weekly paclitaxel + bevacizumab followed by hormone therapy(Treatment of physician's choice) + bevacizumab then back to weekly paclitaxel + bevacizumab"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate optimal usage of bevacizumab to compare which is better, continuing bevacizumab\n      and paclitaxel or switching to hormonal maintenance therapy followed by\n      bevacizumab+paclitaxel after induction therapy of bevacizumab+paclitaxel.\n\n      To examine biomarkers such as monitoring markers of study treatment as exploratory analysis."
        }, 
        "brief_title": "Bevacizumab Plus Paclitaxel Optimization Study With Interventional Maintenance Endocrine Therapy in Advanced or Metastatic ER-positive Human Epidermal Growth Factor Receptor 2(HER2)-Negative Breast Cancer", 
        "condition": "Metastatic Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "1. Histologically confirmed adenocarcinoma of the breast\n\n          2. Female aged 20-75 years old at getting informed consent\n\n          3. HER2 negative disease (IHC 0/1+ or 2+ with FISH negative)\n\n          4. Documented estrogen receptor (ER) positive (>=1% by IHC)\n\n          5. Inoperative locally advanced or metastatic breast cancer at enrolment\n\n          6. Performance status (ECOG): 0-1 at enrolment\n\n          7. Life expectancy of at least 3 months from enrolment\n\n          8. No prior systemic therapy for recurrent breast cancer (excluding hormone therapy)\n\n          9. No prior neo and/or adjuvant chemotherapy with taxane or adjuvant setting with a\n             disease-free interval from completion of the taxane treatment to metastatic diagnosis\n             of >= 12 months\n\n         10. Patients with measurable lesion regarding with Response Evaluation Criteria in Solid\n             Tumors(RECIST) criteria or who have evaluable lesion\n\n         11. Patients with only bone lesion will be acceptable if the osteolytic lesion has a\n             measurable soft tissue component by MRI or CT\n\n         12. No influence on protocol treatment is considered in case prior therapy or\n             examination.\n\n         13. Adequate following organ function within 2 weeks before starting treatment. The\n             latest examination results should be adopted and blood transfusion or treatment of\n             hematopoietic factor drugs is not allowed 2 weeks before examination.\n\n               -  Absolute neutrophil count >= 1500 /mm3 or white blood cell(WBC) count >= 3000\n                  /mm3\n\n               -  Platelets >=10 x 10000 /mm3\n\n               -  Hb >= 9 g/dL\n\n               -  Total bilirubin <= 1.5 mg/dL\n\n               -  aspartate aminotransferase(AST) and alanine aminotransferase(ALT) <= 100\n                  international unit(IU)/L\n\n               -  Serum creatinine <= 1.5 mg/dL\n\n               -  Urine dipstick for proteinuria <= 1+\n\n         14. Written informed consent signed by patients before completing any treatment related\n             procedure"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01989780", 
            "org_study_id": "JBCRG-M04"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm A", 
                    "Arm B"
                ], 
                "intervention_name": "Paclitaxel", 
                "intervention_type": "Drug", 
                "other_name": "Taxol"
            }, 
            {
                "arm_group_label": [
                    "Arm A", 
                    "Arm B"
                ], 
                "intervention_name": "Bevacizumab", 
                "intervention_type": "Drug", 
                "other_name": "Avastin"
            }, 
            {
                "arm_group_label": "Arm B", 
                "intervention_name": "Letrozole", 
                "intervention_type": "Drug", 
                "other_name": "Femara"
            }, 
            {
                "arm_group_label": "Arm B", 
                "intervention_name": "Anastrozole", 
                "intervention_type": "Drug", 
                "other_name": "Arimidex"
            }, 
            {
                "arm_group_label": "Arm B", 
                "intervention_name": "Exemestane", 
                "intervention_type": "Drug", 
                "other_name": "Aromasin"
            }, 
            {
                "arm_group_label": "Arm B", 
                "intervention_name": "Fulvestrant", 
                "intervention_type": "Drug", 
                "other_name": "Faslodex"
            }, 
            {
                "arm_group_label": "Arm B", 
                "intervention_name": "Goserelin", 
                "intervention_type": "Drug", 
                "other_name": "Zoladex"
            }, 
            {
                "arm_group_label": "Arm B", 
                "intervention_name": "leuprorelin acetate", 
                "intervention_type": "Device", 
                "other_name": "Leuplin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Exemestane", 
                "Fulvestrant", 
                "Letrozole", 
                "Anastrozole", 
                "Bevacizumab", 
                "Leuprolide", 
                "Paclitaxel", 
                "Goserelin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 5, 2014", 
        "location": {
            "contact": {
                "email": "office@jbcrg.jp", 
                "phone": "+81-3-6659-7723"
            }, 
            "facility": {
                "address": {
                    "city": "Bunkyo-ku", 
                    "country": "Japan", 
                    "state": "Tokyo", 
                    "zip": "113-0033"
                }, 
                "name": "Japan Breast Cancer Research Group"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "Bevacizumab Plus Paclitaxel Optimization Study With Interventional Maintenance Endocrine Therapy in Advanced or Metastatic ER-positive HER2-negative Breast Cancer -BOOSTER Trial, a Multicenter Randomized Phase II Study-", 
        "overall_contact": {
            "email": "ssaji@kuhp.kyoto-u.ac.jp", 
            "last_name": "Shigehira Saji, MD, PhD", 
            "phone": "+81-75-751-4950"
        }, 
        "overall_official": [
            {
                "affiliation": "Kyoto University, Graduate School of Medicine", 
                "last_name": "Masakazu Toi, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Kyoto University, Graduate School of Medicine", 
                "last_name": "Shigehira Saji, MD, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Time to failure of strategy (TFS)", 
            "safety_issue": "No", 
            "time_frame": "3.5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01989780"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "2y Overall Survival rate", 
                "safety_issue": "No", 
                "time_frame": "3.5 years"
            }, 
            {
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "3.5years"
            }, 
            {
                "measure": "Progression Free Survival(PFS)", 
                "safety_issue": "No", 
                "time_frame": "3.5years"
            }, 
            {
                "measure": "QOL", 
                "safety_issue": "No", 
                "time_frame": "3.5years"
            }, 
            {
                "description": "vascular endothelial growth factor(VEGF)-A, VEGFR-2, VEGF-C, platelet derived growth factor(PDGF)-C, Soluble fms-like tyrosine kinase-1, VEGFR-3, Interleukin(IL)-8, Basic Fibroblast Growth Factor(FGFb), placental growth factor(PLGF), E-Selectin, intercellular adhesion molecule(ICAM)-1, neuropilin of Tumor tissue, single nucleotide polymorphism(SNP):VEGFR-1 and VEGF of whole blood DNA, angiotensin(ANG) and Apelin of serum.", 
                "measure": "Biomarker(IMPACT assay Chips, whole blood, tumor tissue, Serum)", 
                "safety_issue": "No", 
                "time_frame": "3.5years"
            }, 
            {
                "measure": "Safety(Collection of adverse events)", 
                "safety_issue": "Yes", 
                "time_frame": "3.5years"
            }
        ], 
        "source": "Japan Breast Cancer Research Group", 
        "sponsors": {
            "collaborator": {
                "agency": "Chugai Pharmaceutical", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Japan Breast Cancer Research Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}